◀ Back to SP1

MDM2 — SP1

Text-mined interactions from Literome

Johnson-Pais et al., Proc Natl Acad Sci U S A 2001 : We show here that MDM2 inhibits Sp1 mediated transcription, that MDM2 binds directly to Sp1 in vitro as well as in vivo, and that MDM2 inhibits the DNA binding activity of Sp1 ... These results suggest a model in which the opposing activities of MDM2 and pRB regulate Sp1 DNA binding and transcriptional activity
Gu et al., Blood 2002 (Precursor Cell Lymphoblastic Leukemia-Lymphoma) : MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1 binding sites : a novel, p53 independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia
Zhao et al., BMC cancer 2005 : Mdm2 may directly repress activation by both pRB and Sp1 , or activation by NF-Y
Darnell et al., J Biol Chem 2006 : The SerpinB2 mediated elevation of Rb protein levels appeared to be responsible for enhancing transcription from the core promoter region of the LTR by relieving HDM2 mediated inhibition of Sp1 and/or by increasing the Sp1/Sp3 expression ratios
Cattelani et al., Clin Cancer Res 2008 (Genetic Predisposition to Disease...) : MDM2 is a key negative regulator of p53 activity, and a single nucleotide polymorphism ( SNP309, T > G change ; rs 2279744 ) in its promoter increases the affinity for the transcription factor SP1 , enhancing MDM2 expression
Nan et al., Cancer Causes Control 2009 (Genetic Predisposition to Disease...) : A functional MDM2 single nucleotide polymorphism ( SNP309 ) in the promoter region increases the affinity of transcription activator Sp1 for the MDM2 gene promoter, resulting in higher expression of MDM2 and thus inhibition of p53 transcriptional activity